Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07736859
Enrolling by invitation Observational

Satisfaction of Hysterosalpingo-Foam Sonography

NCT07736859 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2026-09
Last updated
2026-07-30

Condition(s) studied

Infertility

Study summary

To evaluate patient satisfaction following a HyFoSy examination performed as part of a fertility workup, by assessing the procedure's tolerability through a questionnaire administered immediately after the examination.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria : * Provided verbal informed consent after receiving full information about the study procedures * Women * Aged 18 years or older * Attending the fertility medicine unit and undergoing a HyFoSy ultrasound examination * Affiliated with, or covered by, a social security health insurance scheme Exclusion Criteria : * Pregnant women * Women who are breastfeeding or in the postpartum period * Non-emancipated minors * Adults under legal protection (guardianship, curatorship, or judicial protection) * Adults unable to provide informed consent * Individuals deprived of liberty by judicial or administrative decision * Individuals receiving involuntary psychiatric care * Individuals who have declined participation in the study

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
CHRU Nancy Nancy France

More Central Hospital, Nancy, France trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07736859 on ClinicalTrials.gov ↗ ← All trials in France